[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352761-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352761-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","engineered-lipid-hybrid-nanoparticles-for-targeted-delivery-of-sh2-superbinder-and-breast-cancer-therapy","Engineered lipid hybrid nanoparticles for targeted delivery of SH2 superbinder and breast cancer therapy","","SH2 Superbinder (SH2S) is an engineered polypeptide tool with enhanced binding to tyrosine-phosphorylated proteins, aiming to improve cancer therapy. Its clinical use is constrained by poor serum stability and insufficient tumor targeting. To address this, SH2S-loaded Lipid Hybrid Nanoparticles (SLHN) are produced using cationic polymer poly(β-amino ester), lipids, and cholesterol with modified microfluidics for intracellular delivery via membrane fusion and clathrin-mediated endocytosis. SLHN blocks AKT/ERK/STAT3 phosphorylation to induce apoptosis and inhibit tumor growth, while SLHN-R with cRGD improves targeting and remodels the tumor microenvironment, enhancing breast cancer treatment at lower doses with milder adverse effects, including synergy with anti-PD-L1. The work demonstrates favorable in vitro and in vivo efficacy, supporting lipid-based protein delivery.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/engineered-lipid-hybrid-nanoparticles-for-targeted-delivery-of-sh2-superbinder-and-breast-cancer-therapy/352761/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/engineered-lipid-hybrid-nanoparticles-for-targeted-delivery-of-sh2-superbinder-and-breast-cancer-therapy/352761.png","ImageObject",300,407,{"name":42,"@type":43},"Jordan Avery","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem limits SH2 Superbinder (SH2S) in clinical use?","Question",{"text":63,"@type":64},"Its poor serum stability and insufficient tumor targeting limit therapeutic performance in clinical translation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does SLHN deliver SH2S into tumor cells?",{"text":68,"@type":64},"SLHN delivers SH2S into tumor cells through membrane fusion and clathrin-mediated endocytosis.",{"name":70,"@type":61,"acceptedAnswer":71},"What advantage does the cRGD modification (SLHN-R) provide for breast cancer therapy?",{"text":72,"@type":64},"SLHN-R improves tumor targeting and modulates the tumor microenvironment by promoting CD8+ T cell infiltration and driving M1 macrophage polarization, enabling efficient treatment at lower dosage with milder adverse effects.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352761,1790318841,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},1099523882367,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Zhu et al. Journal of Nanobiotechnology (2026) 24:358  \n[https://doi.org/10.1186/s12951-026-04249-w](https://doi.org/10.1186/s12951-026-04249-w)  \nJournal of Nanobiotechnology  \nRESEARCH Open Access  \nEngineered lipid hybrid nanoparticles for targeted delivery of SH2 superbinder and breast cancer therapy  \nYuhe Zhu1,2†, Yazhou Sang1,3†, Linna Du3†, Fei Wang2, Jisheng Zhang4, Jianchang Luo1, Caidi He1, Jiawang Lang1*, Songwei Tan2* and Xuan Cao1,3*  \nAbstract  \nSH2 Superbinder (SH2S) is an engineered polypeptide tool derived from the SH2 domain. It exhibits significantly enhanced binding capacity for tyrosine-phosphorylated proteins to treat various cancers. However, its clinical application is limited by poor serum stability and insufficient tumor targeting. To solve these problems, engineered SH2S-loaded Lipid Hybrid Nanoparticles (SLHN) was developed by using cationic polymer poly (β-amino ester), lipids and cholesterol via a modified microfluidic technology. SLHN efficiently delivers the SH2S into tumor cells via membrane fusion and clathrin-mediated endocytosis. Inside cells, it replaces natural proteins containing the SH2 domain, then inducing apoptosis and inhibiting growth in tumor cells by blocking the phosphorylation of AKT, ERK and STAT3 . Furthermore, SLHN modified with cRGD peptide (SLHN-R) exhibits improved tumor targeting capabilities and and the ability to modulate the tumor microenvironment (promoting CD8+ T cell infiltration and driving M1 macrophage polarization), allowing for efficient breast cancer treatment at lower dosage and with milder adverse effects. Combination of SLHN-R and anti-PD-L1 antibody achieved a better tumor suppression effect. In summary, SLHN demonstrates favorable therapeutic effects against breast cancer both in vitro and in vivo. Particularly, when modified by cRGD, it further enhances its efficacy through specific targeting. This modification enriches the application of lipid-based systems in the delivery of anticancer proteins.  \nKeywords SH2 Superbinder, Breast cancer, Protein delivery, Poly (β-amino ester), Nanoparticles  \n†Yuhe Zhu, Yazhou Sang and Linna Du contributed equally to this work.  \n*Correspondence: Jiawang Lang [601803892@qq.com](601803892@qq.com)[ ](601803892@qq.com)Songwei Tan [tansw@hust.edu.cn](tansw@hust.edu.cn)[ ](tansw@hust.edu.cn)Xuan Cao [caoxuanwhu@126.com](caoxuanwhu@126.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nZhu et al. Journal of Nanobiotechnology (2026) 24:358 Page 2 of 19  \nGraphical abstract  \nBackground  \nThe Src Homology 2 (SH2) domain specifically recognizes phosphorylated tyrosine and mediates cell signal transduction, thereby playing a role in targeted cancer therapy [1, 2]. The SH2 Superbinder (SH2S) is a polypeptide tool with triple-point mutants Thr8Val/Cys10Ala/ Lys15Leu, which exhi","cbCaipBqNjzkK8PX","https://ap.wps.com/l/cbCaipBqNjzkK8PX","pdf",4841288,"English","# Background\n# Challenges in SH2S therapy\n## Limitations of prior delivery approaches\n# Intracellular protein delivery strategies\n## Supramolecular self-assembly and nanoparticle systems","[{\"question\":\"What problem limits SH2 Superbinder (SH2S) in clinical use?\",\"answer\":\"Its poor serum stability and insufficient tumor targeting limit therapeutic performance in clinical translation.\"},{\"question\":\"How does SLHN deliver SH2S into tumor cells?\",\"answer\":\"SLHN delivers SH2S into tumor cells through membrane fusion and clathrin-mediated endocytosis.\"},{\"question\":\"What advantage does the cRGD modification (SLHN-R) provide for breast cancer therapy?\",\"answer\":\"SLHN-R improves tumor targeting and modulates the tumor microenvironment by promoting CD8+ T cell infiltration and driving M1 macrophage polarization, enabling efficient treatment at lower dosage with milder adverse effects.\"}]","Engineered lipid hybrid nanoparticles for targeted delivery of SH2 superbinder and breast cancer therapy | PDF",1790101261,48,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a4f7a391ae9b22e2aca141f30d7c84e.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b3aace44e4278583d76ad50efee241f.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/edc237634eafa3d84423e1cf6d2eaf52.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/00815c7c256800392d31c8fd770afcb1.webp",980,1306]